Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217266 · ClinicalTrials.gov registry record · Phase 1
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03217266: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03217266 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03217266, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This phase Ib trial studies the side effects of navtemadlin and radiation therapy in treating patients with soft tissue sarcoma. Navtemadlin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving navtemadlin and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- RADIATION Radiation Therapy
- PROCEDURE Surgical Procedure
- DRUG Navtemadlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217266
The ClinicalTrials.gov registry entry for NCT03217266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT03217266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217266 about?
NCT03217266 is a clinical study titled "Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma". This phase Ib trial studies the side effects of navtemadlin and radiation therapy in treating patients with soft tissue sarcoma. Navtemadlin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and s...
What is the current status of trial NCT03217266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2018-06-20. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT03217266?
The interventions under investigation include: Radiation Therapy (RADIATION), Surgical Procedure (PROCEDURE), Navtemadlin (DRUG).
Who is sponsoring clinical trial NCT03217266?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.